Generate Biomedicines, founded in 2018 and based in Somerville, Massachusetts, has raised a total of $643 million to date. The company secured $50 million in its Series A round in September 2020 led by Flagship Pioneering, followed by a $370 million Series B in November 2021, and a $273 million Series C in September 2023 led by Alumni Ventures. Focused on AI-driven generative biology, Generate Biomedicines designs novel protein therapeutics across immunology, oncology, and infectious diseases, aiming to revolutionize modern drug discovery and development.